Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Bristol-Myers Squibb Co And Bristol-Myers Squibb Announces Top Line Results For SAVOR-TIMI-53 Cardiovascular Outcomes Trial Of Onglyza (saxagliptin)


Wednesday, 19 Jun 2013 02:02am EDT 

Bristol-Myers Squibb Co and AstraZeneca PLC announced top line results of the Phase 4 SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial of Onglyza (saxagliptin). In this study of adult patients with type 2 diabetes with either a history of established cardiovascular disease or multiple risk factors, Onglyza met the primary safety objective of non-inferiority, and did not meet the primary efficacy objective of superiority, for a composite endpoint of cardiovascular death, non-fatal myocardial infarction or non-fatal ischaemic stroke, when added to a patient's current standard of care (with or without other anti-diabetic therapies), as compared to placebo. 

Company Quote

4042.5
82.5 +2.08%
12:14pm EDT